Abstract:Contrast-enhanced magnetic resonance imaging (MRI) of the liver and pancreas is frequently performed to improve the sensitivity and specificity of lesion detection in these organs. The concept of using tissue-specific contrast media is to selectively enhance the normal parenchyma, but not lesions, so that the contrast between tumorous and normal tissue is increased, and lesion detectability improved. Mangafodipir trisodium (MnDPDP) has been developed as a hepatocellular-specific contrast agent, but uptake has also been found in pancreatic tissue. In this study the safety and diagnostic efficacy of MnDPDP were investigated in both healthy volunteers and in patients with liver and pancreatic tumors. In healthy volunteers (n = 8), dose-dependent enhancement in T1-weighted images was observed in the normal liver and pancreatic parenchyma after infusion of MnDPDP at doses of 5 and 10 mumol/kg. The maximal enhancement in the two dose groups was 77 and 110% in the liver, and 57 and 84% in the pancreas, respectively. The enhancement-over-time profiles demonstrated that the effective imaging window was about 2 h for the liver, and over 4 h for the pancreas. There was no measurable enhancement in brain structures protected by intact blood-brain barrier, and no changes of clinical importance were found in vital signs or in blood and urinary chemistry variables. Compared with unenhanced images (including T2-weighted images), significantly more lesions were detected on MnDPDP-enhanced T1 images in 82 patients with liver tumors (mostly metastases). Features such as rim enhancement and the enhancement in hepatocellular carcinomas can provide information for differential diagnosis. In a study on patients with pancreatic tumors, mainly adenocarcinomas (n = 21) and islet cell tumors (n = 19), two additional lesions were found in the MnDPDP-enhanced images. The contrast enhancement in the pancreatic parenchyma can vary greatly, depending on the site of the enhancing part of the organ in relation to a large tumor. The tumors of both origins were also enhanced post-contrast, but to a lesser degree than the normal pancreatic tissue. MnDPDP enhancement was investigated in 30 liver metastases from endocrine tumors in 13 patients. These lesions showed a signal increase of about 49% post-contrast, which lasted longer than that in the normal liver tissue. The findings may help to distinguish these tumors from other metastatic tumors. T1-weighted sequences of four types, including a spin-echo and three variants of fast gradient-echo sequences, and various parameter combinations, were investigated in healthy volunteers (n = 6), with the aim of finding the optimal sequence for MnDPDP-enhanced MRI of the liver and pancreas. The fat-and-water out-of-phase, fast field (gradient)-echo sequence was the best for imaging of both the liver and pancreas. The studies have shown that MnDPDP is safe when given as an infusion, and is effective as a liver- and pancreas-specific contrast medium, with improved lesion detection in MRI of these organs. It is also useful for the characterization of liver tumors.

Mangafodipir Trisodium (Mndpdp)-Enhanced Magnetic Resonance Imaging of the Liver and Pancreas.

MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue

Manganese-Enhanced Mri Of Hypoxic-Ischemic Brain Injuries Using Mn-Dpdp

MR imaging of the stomach: potential use for mangafodipir trisodium--a study in swine.

The Development of Dendritic Gd-Dtpa Complexes for Mri Contrast Agents

Preparation of Mn2+@PolyDOPA-b-polysarcosine Micelle As MRI Contrast Agent with High Longitudinal Relaxivity

Gd-EOB-DTPA-enhanced Magnetic Resonance Imaging for Focal Liver Lesions in Chinese Patients: a Multicenter, Open-Label, Phase III Study.

Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.

Lipophilic Group-Modified Manganese(II)-Based Contrast Agents for Vascular and Hepatobiliary Magnetic Resonance Imaging.

Biocompatible Nanocomplexes for Molecular Targeted MRI Contrast Agent

Mn(II) Complex of Lipophilic Group-Modified Ethylenediaminetetraacetic Acid (EDTA) As a New Hepatobiliary MRI Contrast Agent

Preparation and performance of biocompatible gadolinium polymer as liver-targeting magnetic resonance imaging contrast agent

Mn(II)-monosubstituted polyoxometalates as candidates for contrast agents in magnetic resonance imaging.

Initial Clinical Appoication of Teslascan(mndpdp)

Imaging liver metastases with a new oral manganese-based contrast agent

Study of Clinical Application of Hepatic-Biliary Specific MR Contrast Agent(gd-Eob-dtpa) in the Diagnosis of Focal Hepatic Lesions

Comparison Between Gd-Dtpa and Several Bisamide Derivatives As Potential Mri Contrast Agents

Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging.

Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.

A Biocompatible Gadolinium (III)-Poly (Aspartic Acid-Co-Phenylalanine) for Liver Magnetic Resonance Imaging Contrast Agent